Professor Daniela Zisterer

• Treatment of Chronic Myeloid leukaemia: current practise and future prospects in, editor(s)Steffen Koschmieder and Utz Krug , Myeloid Leukemia Clinical Diagnosis & Treatment, Croatia, Intech, 2011, pp1 - 24, [Daniela M. Zisterer]Book Chapter, 2011
• Diez-Cecilia, E. Kelly, B. Perez, C. Zisterer, D.M. Nevin, D.K. Lloyd, D.G. Rozas, I., Guanidinium-based derivatives: Searching for new kinase inhibitors, European Journal of Medicinal Chemistry, 81, 2014, p427 - 441Journal Article, 2014, DOI , URL
• O'Callaghan K, Palagano E, Butini S, Campiani G, Williams DC, Zisterer DM, O'Sullivan J, Induction of apoptosis in oral squamous carcinoma cells by pyrrolo-1,5-benzoxazepines., Molecular medicine reports, 12, (3), 2015, p3748-54Journal Article, 2015, DOI , TARA - Full Text
• Fiore D, Proto MC, Pisanti S, Picardi P, Pagano Zottola AC, Butini S, Gemma S, Casagni A, Laezza C, Vitale M, Ligresti A, Di Marzo V, Zisterer DM, Nathwani S, Williams DC, Campiani G, Gazzerro P, Bifulco M, Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells., Cancer biology & therapy, 17, (8), 2016, p849 - 858Journal Article, 2016, DOI
• Greene LM, Meegan MJ, Zisterer DM, Combretastatins: More Than Just Vascular Targeting Agents?, The Journal of pharmacology and experimental therapeutics, 355, (2), 2015, p212-27Journal Article, 2015
• Spallarossa A, Caneva C, Caviglia M, Alfei S, Butini S, Campiani G, Gemma S, Brindisi M, Zisterer DM, Bright SA, Williams CD, Crespan E, Maga G, Sanna G, Delogu I, Collu G, Loddo R, Unconventional Knoevenagel-type indoles: Synthesis and cell-based studies for the identification of pro-apoptotic agents., European journal of medicinal chemistry, 102, 2015, p648-60Journal Article, 2015, DOI
• Kinsella P, Greene LM, Bright SA, Pollock JK, Butini S, Campiani G, Bauer S, Williams DC, Zisterer DM, The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15., Investigational new drugs, 34, (2), 2016, 159-167Journal Article, 2016, DOI
• Kelly PM, Bright SA, Fayne D, Pollock JK, Zisterer DM, Williams DC, Meegan MJ, Synthesis, antiproliferative and pro-apoptotic activity of 2-phenylindoles., Bioorganic & medicinal chemistry, 24, (18), 2016, p4075-99Journal Article, 2016, DOI
• Lennon JC, Butini S, Campiani G, O'Meara A, Williams DC, Zisterer DM, Involvement of AMP-activated protein kinase in mediating pyrrolo-1,5-benzoxazepine-induced apoptosis in neuroblastoma cells., Investigational new drugs, 34, (5), 2016, p663-76Journal Article, 2016, DOI
• Nathwani SM, Greene LM, Butini S, Campiani G, Williams DC, Samali A, Szegezdi E, Zisterer DM, The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL"induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells., International journal of oncology, 49, (1), 2016, p74-88Journal Article, 2016, DOI
• Kahvedzic -Seljubac A, Nathwani S.-M, Zisterer D.M, Rozas I, Isouronium and N-hydroxyguanidinium derivatives as Cell growth inhibitors: A comparative study, European Journal of Medicinal Chemistry, 117, 2016, p269 - 282Journal Article, 2016, DOI , URL
• Greene TF, Wang S, Greene LM, Nathwani SM, Pollock JK, Malebari AM, McCabe T, Twamley B, O'Boyle NM, Zisterer DM, Meegan MJ, Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylazetidin-2-ones as Tubulin-Targeting Antitumor Agents., Journal of Medicinal Chemistry, 59, (1), 2016, p90 - 113Journal Article, 2016, DOI , URL , TARA - Full Text
• Brindisi M, Maramai S, Brogi S, Fanigliulo E, Butini S, Guarino E, Casagni A, Lamponi S, Bonechi C, Nathwani SM, Finetti F, Ragonese F, Arcidiacono P, Campiglia P, Valenti S, Novellino E, Spaccapelo R, Morbidelli L, Zisterer DM, Williams CD, Donati A, Baldari C, Campiani G, Ulivieri C, Gemma S., Development of novel cyclic peptides as pro-apoptotic agents., European Journal of Medicinal Chemistry, 117, 2016, p301 - 320Journal Article, 2016, DOI
• Carr M, Knox AJ, Lloyd DG, Zisterer DM, Meegan MJ., Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells., Journal of Enzyme Inhibition and Medicinal Chemistry, 31, 2016, p117-130Journal Article, 2016, DOI
• Meegan MJ, Nathwani S, Twamley B, Zisterer DM, O'Boyle NM., Piperlongumine (piplartine) and analogues: Antiproliferative microtubule-destabilising agents., European Journal of Medicinal Chemistry, 125, 2017, p453 - 463Journal Article, 2017, DOI , TARA - Full Text
• Greene LM, Nathwani SM, Zisterer DM., Inhibition of γ-secretase activity synergistically enhances tumour necrosis factor-related apoptosis-inducing ligand induced apoptosis in T-cell acute lymphoblastic leukemia cells via upregulation of death receptor 5., Oncology Letters, 12, (4), 2016, p2900 - 2905Journal Article, 2016, DOI
• Greene L.M, Butini S, Campiani G, Williams D.C, Zisterer D.M, Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepines, Journal of Cancer, 7, (15), 2016, p2367 - 2377Journal Article, 2016, DOI , URL
• O'Boyle NM, Pollock JK, Carr M, Knox AJ, Nathwani SM, Wang S, Caboni L, Zisterer DM, Meegan MJ., β-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand., Journal of medicinal chemistry, 57, (22), 2014, p9370-9382Journal Article, 2014, DOI
• Daniela Zisterer, Mary Meegan, Niamh O'Boyle, Miriam Carr, Lisa Greene and Thomas Greene, 'Combretastatin Derivatives and Uses Therefor', European Patent Office, EP2338877 A1, 2009Patent, 2009, URL
• Malebari, AM, Greene, LM, Nathwani, SM, Fayne, D, O'Boyle, NM, Wang, S, Twamley, B, Zisterer, DM, Meegan, MJ, Beta-lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells, European Journal of Medicinal Chemistry, 130, 2017, p261-285Journal Article, 2017, DOI , URL
• O'Boyle, NM, Barrett, I, Greene, LM, Carr, M, Fayne, D, Twamley, B, Knox, AJS, Keely, NO, Zisterer, DM, Meegan, MJ, Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ER-alpha and ER-beta Activity, Journal of Medicinal Chemistry, 61, (2), 2018, p514 - 534Journal Article, 2018, DOI , URL , TARA - Full Text
• Pollock JK, Greene LM, Nathwani SM, Kinsella P, O'Boyle NM, Meegan MJ, Zisterer DM., Involvement of NF-kB in mediating the anti-tumour effects of combretastatins in T cells., Investigational new drugs, 36, (4), 2018, p523-535Journal Article, 2018, DOI
• Kelly PM, Keely NO, Bright SA, Yassin B, Ana G, Fayne D, Zisterer DM, Meegan MJ., Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation., Molecules (Basel, Switzerland), 22, (9), 2017, p1440-Journal Article, 2017, DOI , TARA - Full Text
• Geoghegan F, Chadderton N, Farrar GJ, Zisterer DM, Porter RK., Direct effects of phenformin on metabolism/bioenergetics and viability of SH-SY5Y neuroblastoma cells., Oncology letters, 14, (5), 2017, p6298-6306Journal Article, 2017, DOI
• Previtali, V. and Trujillo, C. and Amet, R. and Zisterer, D.M. and Rozas, I., Effect of isouronium/guanidinium substitution on the efficacy of a series of novel anti-cancer agents, MedChemComm, 9, (4), 2018, p735-743Journal Article, 2018, DOI , URL
• Margherita Brindisi, Cristina Ulivieri, Gloria Alfano, Sandra Gemma,Francisco de Asís Balaguer, Tuhina Khan, Alessandro Grillo, Giulia Chemi, Grégory Menchon, Andrea E. Prota, Natacha Olieric, Daniel Lucena-Agell, Isabel Barasoain, J. Fernando Diaz, Angela Nebbioso, Maria Rosaria Conte, Ludovica Lopresti, Stefania Magnano, Rebecca Amet, Paula Kinsella, Daniela M. Zisterer, Ola Ibrahim, Jeff O'Sullivan, Lucia Morbidelli, Roberta Spaccapelo, Cosima Baldari, Stefania Butini, Ettore Novellino, Giuseppe Campiani, Lucia Altucci, Michel Steinmetz, Simone Brogi, Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents, European Journal of Medicinal Chemistry, 2019, p290-320Journal Article, 2019, DOI , URL , TARA - Full Text
• S. Federico, T. Khan, N. Relitti , G. Chemi, M. Brindisi , S. Brogi, E. Novellino, D.M. Zisterer, G. Campiani, S. Gemma, S. Butini, A Jocic-type approach for a practical and scalable synthesis of pyrrolonaphthoxazepine (PNOX)-based potent proapoptotic agents, Tetrahedron Letters, 2018Journal Article, 2018, DOI , TARA - Full Text
• Saraswati AP, Relitti N, Brindisi M, Gemma S, Zisterer D, Butini S & Campiani G, Raising the bar in anticancer therapy:recent advances in, and perspectives on, telomerase inhibitors, Drug Discovery Today, 2019Journal Article, 2019, DOI , TARA - Full Text
• Wang, S., Malebari, A.M., Greene, T.F., O'Boyle, N.M., Fayne, D., Nathwani, S.M., Twamley, B., McCabe, T., Keely, N.O., Zisterer, D.M. and Meegan, M.J., 3-Vinylazetidin-2-Ones: Synthesis, antiproliferative and tubulin destabilizing activity in MCF-7 and MDA-MB-231 Breast Cancer Cells, Pharmaceuticals, 12, (2), 2019Journal Article, 2019, DOI
• Coyle, R. and Slattery, K. and Ennis, L. and O'Sullivan, M.J. and Zisterer, D.M. , The XIAP inhibitor embelin sensitises malignant rhabdoid tumour cells to TRAIL treatment via enhanced activation of the extrinsic apoptotic pathway, International Journal of Oncology, 55, (1), 2019, p191-202Journal Article, 2019, DOI , URL
• O'Boyle, N.M. and Ana, G. and Kelly, P.M. and Nathwani, S.M. and Noorani, S. and Fayne, D. and Bright, S.A. and Twamley, B. and Zisterer, D.M. and Meegan, M.J., Synthesis and evaluation of antiproliferative microtubule-destabilising combretastatin A-4 piperazine conjugates, Organic and Biomolecular Chemistry, 17, (25), 2019, p6184-6200Journal Article, 2019, DOI , URL
• M. M. Mc Gee, E. Hyland, G. Campiani, A. Ramunno, V. Nacci and D. M. Zisterer, Caspase-3 is not essential for DNA fragmentation in MCF-7 cells during apoptosis induced by the pyrrolo-1,5-benzoxazepine, PBOX-6, FEBS letters, 515, (1-3), 2002, p66-70Journal Article, 2002, DOI , URL
• M. M. Mc Gee, G. Campiani, A. Ramunno, V. Nacci, M. Lawler, D. C. Williams and D. M. Zisterer, Activation of the c-Jun N-terminal kinase (JNK) signaling pathway is essential during PBOX-6-induced apoptosis in chronic myelogenous leukemia (CML) cells, The Journal of Biological Chemistry, 277, (21), 2002, p18383-18389Journal Article, 2002, DOI , URL
• D. M. Zisterer, P. N. Moynagh and D. C. Williams, Hexachlorocyclohexanes inhibit steroidogenesis in Y1 cells. Absence of correlation with binding to the peripheral-type benzodiazepine binding site, Biochemical Pharmacology, 51, (10), 1996, p1303-1308Journal Article, 1996, DOI , URL
• D. M. Zisterer, M. M. McGee, G. Campiani, A. Ramunno, C. Fattorusso, V. Nacci, M. Lawler and D. C. Williams, Pyrrolo-1,5-benzoxazepines: a new class of apoptotic agents, Biochemical Society transactions, 29, (6), 2001, p704-706Journal Article, 2001, URL
• M. M. Mc Gee, L. M. Greene, S. Ledwidge, G. Campiani, V. Nacci, M. Lawler, D. C. Williams and D. M. Zisterer, Selective induction of apoptosis by the pyrrolo-1,5-benzoxazepine 7-[[dimethylcarbamoyl]oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in Leukemia cells occurs via the c-Jun NH2-terminal kinase-dependent phosphorylation and inactivation of Bcl-2 and Bcl-XL, The Journal of pharmacology and experimental therapeutics, 310, (3), 2004, p1084-1095Journal Article, 2004, DOI , URL
• M. M. Mc Gee, G. Campiani, A. Ramunno, C. Fattorusso, V. Nacci, M. Lawler, D. C. Williams and D. M. Zisterer, Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl, The Journal of Pharmacology and Experimental Therapeutics, 296, (1), 2001, p31-40Journal Article, 2001, URL
• D. M. Zisterer, C. Sunol, P. N. Moynagh, D. C. Williams and E. Rodriguez-Farre, PK 11195 reduces the brain availability of lindane in rats and the convulsions induced by this neurotoxic agent, Life Sciences, 57, (25), 1995, p2359-2364Journal Article, 1995, DOI , URL
• M. M. Mc Gee, G. Campiani, A. Ramunno, C. Fattorusso, V. Nacci, M. Lawler, D. C. Williams and D. M. Zisterer, Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myeloid leukemia (cml) cells by bypassing the apoptotic suppressor bcr-abl, TheScientificWorldJournal [electronic resource], 1, (1 Suppl 3), 2001, p109Journal Article, 2001, URL
• M. Marangolo, M. M. McGee, K. F. Tipton, D. C. Williams and D. M. Zisterer, Oxidative stress induces apoptosis in C6 glioma cells: involvement of mitogen-activated protein kinases and nuclear factor kappa B, Neurotox Research, 3, (4), 2001, p397-409Journal Article, 2001, DOI , URL
• Miriam Carr, Andrew J.S. Knox, Daniel K. Nevin, Niamh O'Boyle, Shu Wang, Billy Egan, Thomas McCabe, Brendan Twamley, Daniela M. Zisterer, David G. Lloyd, Mary J. Meegan, Optimisation of Estrogen Receptor Subtype-Selectivity of a 4-Aryl-4H-Chromene Scaffold Previously Identified by Virtual Screening, Bioorganic & Medicinal Chemistry, 28, (5), 2020, p115261-Journal Article, 2020
• Azizah M. Malebari, Darren Fayne, Seema M. Nathwani, Fiona O'Connell, Sara Noorani, Brendan Twamley, Niamh M. O'Boyle, Jacintha O'Sullivan, Daniela M. Zisterer, Mary J. Meegan, Beta-lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells, European Journal of Medicinal Chemistry, 189, 2020, p112050-Journal Article, 2020, DOI , URL
• M. M. Mc Gee, G. Campiani, A. Ramunno, C. Fattorusso, V. Nacci, M. Lawler, D. C. Williams and D. M. Zisterer, Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl, The Journal of pharmacology and experimental therapeutics, 296, (1), 2001, p31-40Journal Article, 2001, URL
• M. M. Mc Gee, G. Campiani, A. Ramunno, C. Fattorusso, V. Nacci, M. Lawler, D. C. Williams and D. M. Zisterer, Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myeloid leukemia (cml) cells by bypassing the apoptotic suppressor bcr-abl, TheScientificWorldJournal [electronic resource], 1, (1 Suppl 3), 2001, p109Journal Article, 2001, URL
• A. Prasanth Saraswati, Nicola Relitti, Margherita Brindisi, Jeremy D. Osko, Giulia Chemi, Stefano Federico, Alessandro Grillo, Simone Brogi, Niamh H. McCabe, Richard C. Turkington, Ola Ibrahim, Jeffrey O'Sullivan, Stefania Lamponi, Magda Ghanim, Vincent P. Kelly, Daniela Zisterer, Rebecca Amet, Patricia Hannon, Francesca Vanni, Cristina Ulivieri, Daniel Herp, Federica Sarno, Antonella Di Costanzo, Fulvio Saccoccia, Giovina Ruberti, Manfred Jung, Lucia Altucci, Sandra Gemma, Stefania Butini, David W. Christianson, and Giuseppe Campiani, Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, 2 Synthesis, Structural Analysis, and Biological Evaluation , ACS Medicinal Chemistry Letters, 2020Journal Article, 2020, DOI , URL , TARA - Full Text
• McGee, MM, Gemma, S, Rammunno, A, Zisterer,DM, Fatterusso, C, Catalanotti, B, Butini, S, Fiorini,I, Pisano, C, Cucco, C, Novellino, E, Nacci, V, Williams, DC and Campiani, G, Pyrolo [1,5] benzoxathiazepines as a new class of potent apoptotic agents. Biological studies and identification of an intracellular location of their drug target., Journal of Medicinal Chemistry, 48, (13), 2005, p4367 - 4377Journal Article, 2005, DOI , URL
• Gloria Ana, Patrick M. Kelly, Azizah M. Malebari, Sara Noorani, Seema M. Nathwani, Brendan Twamley, Darren Fayne, Niamh M. O'Boyle, Daniela M. Zisterer, Elisangela Flavia Pimentel, Denise Coutinho Endringer and Mary J. Meegan, Synthesis and Biological Evaluation of 1-(Diarylmethyl)-1H-1,2,4-Triazoles and 1-(Diarylmethyl)-1H-Imidazoles as a Novel Class of Anti-Mitotic Agent for Activity in Breast Cancer, Pharmaceuticals, 14, (2), 2021, p169-Journal Article, 2021, DOI , URL
• Viola Previtali , Helene B Mihigo , Rebecca Amet, Anthony M McElligott , Daniela M Zisterer , Isabel Rozas , Exploring the Anti-Cancer Mechanism of Novel 3,4'-Substituted Diaryl Guanidinium Derivatives, Pharmaceuticals (Basel), 13, (12), 2020, p485Journal Article, 2020, DOI
• Magnano S, Hannon Barroeta P, Duffy R, O'Sullivan J, Zisterer DM., Cisplatin induces autophagy-associated apoptosis in human oral squamous cell carcinoma (OSCC) mediated in part through reactive oxygen species., Toxicology and applied pharmacology, 427, 2021, p115646Journal Article, 2021, DOI
• Rebecca Amet, Viola Previtali, Helene B. Mihigo, Emily Sheridan, Sarah Brophy , Nadhim Kamil Hante, Maria Jose Santos-Martinez, Patrick J. Hayden, Paul V. Browne, Isabel Rozas, Anthony M. McElligott , Daniela M. Zisterer , A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma , Life Sciences, 290, 2022Journal Article, 2022, DOI , TARA - Full Text
• Malebari A.M., Wang S., Greene T.F., O'Boyle N.M., Fayne D., Khan M.F., Nathwani S.M., Twamley B., McCabe T., Zisterer D.M., Meegan M.J., Synthesis and antiproliferative evaluation of 3-chloroazetidin-2-ones with antimitotic activity: Heterocyclic bridged analogues of combretastatin A-4, Pharmaceuticals, 14, (11), 2021, part. 1119-Journal Article, 2021, DOI
• Malebari, A.M. and Fayne, D. and Nathwani, S.M. and O'Connell, F. and Noorani, S. and Twamley, B. and O'Boyle, N.M. and O'Sullivan, J. and Zisterer, D.M. and Meegan, M.J., Beta-Lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells, European Journal of Medicinal Chemistry, 189, (112050), 2020Journal Article, 2020, DOI , URL
• Malebari, A.M. and Greene, L.M. and Nathwani, S.M. and Fayne, D. and O'Boyle, N.M. and Wang, S. and Twamley, B. and Zisterer, D.M. and Meegan, M.J., β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells, European Journal of Medicinal Chemistry, 130, 2017, p261-285Journal Article, 2017, DOI , URL
• Campiani, G. and Khan, T. and Ulivieri, C. and Staiano, L. and Papulino, C. and Magnano, S. and Nathwani, S. and Ramunno, A. and Lucena-Agell, D. and Relitti, N. and Federico, S. and Pozzetti, L. and Carullo, G. and Casagni, A. and Brogi, S. and Vanni, F. and Galatello, P. and Ghanim, M. and McCabe, N. and Lamponi, S. and Valoti, M. and Ibrahim, O. and O'Sullivan, J. and Turkington, R. and Kelly, V.P. and VanWemmel, R. and Díaz, J.F. and Gemma, S. and Zisterer, D. and Altucci, L. and De Matteis, A. and Butini, S. and Benedetti, R., Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy, European Journal of Medicinal Chemistry, 235, (114274), 2022Journal Article, 2022, DOI , URL
• Vanni, F. and Lopresti, L. and Zurli, V. and Kabanova, A. and Cattaneo, F. and Sicuranza, A. and Gozzetti, A. and Gemma, S. and Zisterer, D.M. and Bocchia, M. and Campiani, G. and Baldari, C.T. and Butini, S. and Ulivieri, C., A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in EÎŒ-TCL1 mice through the JNK/STAT4/p66Shc axis, Pharmacological Research, 174, (105965), 2021Journal Article, 2021, DOI , URL
• Khan, T. and Relitti, N. and Brindisi, M. and Magnano, S. and Zisterer, D. and Gemma, S. and Butini, S. and Campiani, G., Autophagy modulators for the treatment of oral and esophageal squamous cell carcinomas, Medicinal Research Reviews, 40, (3), 2020, p1002-1060Journal Article, 2020, DOI , URL
• Relitti, N. and Saraswati, A.P. and Federico, S. and Khan, T. and Brindisi, M. and Zisterer, D. and Brogi, S. and Gemma, S. and Butini, S. and Campiani, G., Telomerase-based cancer therapeutics: A review on their clinical trials, Current Topics in Medicinal Chemistry, 20, (6), 2020, p433-457Journal Article, 2020, DOI , URL
• Keely, N.O. and Carr, M. and Yassin, B. and Ana, G. and Lloyd, D.G. and Zisterer, D. and Meegan, M.J., Design, synthesis and biochemical evaluation of novel selective estrogen receptor ligand conjugates incorporating an endoxifen-combretastatin hybrid scaffold, Biomedicines, 4, (3), 2016Journal Article, 2016, DOI , URL
• Gangemi, G. and Gazzerro, P. and Fiore, D. and Chiara Proto, M. and Butini, S. and Gemma, S. and Casagni, A. and Laezza, C. and Vitale, M. and Ligresti, A. and Dimarzo, V. and Zisterer, D.M. and Nathwani, S. and Clive Williams, D. and Campiani, G. and Bifulco, M., Erratum: PBOX-15 induces apoptosis and improves the efficacy of oxaliplatin in human colorectal cancer cell lines (European Journal of Pharmacology (2013) 714:1-3 (379-387)), European Journal of Pharmacology, 728, (1), 2014, p190Journal Article, 2014, DOI , URL
• Malebari AM, Duffy Morales G, Twamley B, Fayne D, Khan MF, McLoughlin EC, O'Boyle NM, Zisterer DM, Meegan MJ., Synthesis, Characterisation and Mechanism of Action of Anticancer 3-Fluoroazetidin-2-ones., Pharmaceuticals (Basel, Switzerland), 15, (9), 2022, p1044Journal Article, 2022, DOI
• McCabe, N.H. and Stevenson, L. and Scanlon, E. and Douglas, R. and Kennedy, S. and Keminer, O. and WindshÃŒgel, B. and Zisterer, D. and Kennedy, R.D. and Blayney, J.K. and Turkington, R.C., Identification of Src as a Therapeutic Target in Oesophageal Adenocarcinoma through Functional Genomic and High-Throughput Drug Screening Approaches, Cancers, 14, (15), 2022Journal Article, 2022, DOI , URL
• Hannon Barroeta, P. and Magnano, S. and O'Sullivan, M.J. and Zisterer, D.M., Evaluation of targeting autophagy for the treatment of malignant rhabdoid tumours, Cancer Treatment and Research Communications, 32, (100584), 2022Journal Article, 2022, DOI , URL
• Coyle, R. and O'Sullivan, M.J. and Zisterer, D.M., Targeting inhibitor of apoptosis proteins (IAPs) with IAP inhibitors sensitises malignant rhabdoid tumour cells to cisplatin, Cancer Treatment and Research Communications, 32, (100579), 2022Journal Article, 2022, DOI , URL
• Malebari, A.M. and Fayne, D. and Nathwani, S.M. and O'Connell, F. and Noorani, S. and Twamley, B. and O'Boyle, N.M. and O'Sullivan, J. and Zisterer, D.M. and Meegan, M.J., β-Lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells, European Journal of Medicinal Chemistry, 189, (112050), 2020Journal Article, 2020, DOI , URL
• Wang S., Malebari A.M., Greene T.F., Kandwal S., Fayne D., Nathwani S.M., Zisterer D.M., Twamley B., O'Boyle N.M., Meegan M.J., Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells, Pharmaceuticals, 16, (7), 2023, p1000-Journal Article, 2023, DOI , URL
• McLoughlin E.C., Twamley B., O'Brien J.E., Hannon Barroeta P., Zisterer D.M., Meegan M.J., O'Boyle N.M., Synthesis by diastereomeric resolution, biochemical evaluation and molecular modelling of chiral 3-hydroxyl b-lactam microtubule-targeting agents for the treatment of triple negative breast and chemoresistant colorectal cancers, Bioorganic Chemistry, 141, 2023Journal Article, 2023, DOI , URL
• Byrne A.J., Bright S.A., McKeown J.P., Bergin A., Twamley B., McElligott A.M., Noorani S., Kandwal S., Fayne D., O'Boyle N.M., Williams D.C., Meegan M.J., Synthesis and Pro-Apoptotic Effects of Nitrovinylanthracenes and Related Compounds in Chronic Lymphocytic Leukaemia (CLL) and Burkitt's Lymphoma (BL), Molecules, 28, (24), 2023Journal Article, 2023, DOI
• Gao, T. and Magnano, S. and Rynne, A. and O'Kane, L. and Barroeta, P.H. and Zisterer, D.M., Targeting inhibitor of apoptosis proteins (IAPs) enhances susceptibility of oral squamous carcinoma cells to cisplatin, Experimental Cell Research, 437, (1), 2024Journal Article, 2024, DOI , URL
• Hannon Barroeta, P. and O†Sullivan, M.J. and Zisterer, D.M., The role of the Nrf2/GSH antioxidant system in cisplatin resistance in malignant rhabdoid tumours, Journal of Cancer Research and Clinical Oncology, 149, (11), 2023, p8379-8391Journal Article, 2023, DOI , URL
• Lloyd DG, Hughes RB, Zisterer DM, Williams DC, Fattorusso C, Catalanotti B, Campiani G, Meegan MJ., Benzoxepin-derived estrogen receptor modulators: a novel molecular scaffold for the estrogen receptor, Journal of Medicinal Chemistry, 47, (23), 2004, p5612 - 5615Journal Article, 2004, DOI , URL
• Lloyd DG, Smith HM, O'Sullivan T, Zisterer DM, Meegan MJ, Synthesis, Structure-Activity Relationships and Antagonistic Effects in Human MCF-7 Breast Cancer Cells of Flexible Estrogen Receptor Modulators, Medicinal Chemistry, 1, (4), 2005, p335 - 353Journal Article, 2005, DOI , URL
• McKenna, S.M. and Florea, B.I. and Zisterer, D.M. and van Kasteren, S.I. and McGouran, J.F., Probing the metalloproteome: an 8-mercaptoquinoline motif enriches minichromosome maintenance complex components as significant metalloprotein targets in live cells, RSC Chemical Biology, 5, (8), 2024, p776-786Journal Article, 2024, DOI , URL
• Greene, L.M., Fleeton, M., Mulligan, J., Chikana, G., Sheahan, B.J., Atkins, G.J., Campiani, G., Nacci, V., Lawler, M., Williams, D.C. and Zisterer, D.M., The pyrrolo-1,5-benzoxazepine, PBOX-6, inhibits the growth of breast cancer cells in vitro independent of estrogen receptor status, and inhibits breast tumour growth in vivo, Oncology Reports, 14, 2005, p1357 - 1363Journal Article, 2005
• Mulligan J.M., Campiani G., Ramunno A., Nacci V., Zisterer D.M. , Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human astrocytoma cells by pyrrolo-1,5-benzoxazepine, PBOX-21., Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1639, (1), 2003, p43 - 52Journal Article, 2003, DOI , URL
• Quinlan, C.A., O'Sullivan, M.I., Zisterer, D.M. & Tipton, K.F., In vitro cytotoxicity of a composite resin and compomer., International Endodontic Journal, 35, (1), 2002, p47 - 55Journal Article, 2002, DOI , URL
• Campiani, G., Ramuno, A., Fiorini, I., Nacci, V., Morelli, E., Novellino, E., Menninni, T., Zisterer, D.M., Williams, D.C. , Synthesis of new molecular probes for investigation of steroid biosynthesis induced by selective interaction with peripheral-type benzodiazepine receptors (PBR)., Journal Medicinal Chemistry, 45, (19), 2002, p4276 - 4281Journal Article, 2002, DOI , URL
• Meegan, M., Hughes, R., Lloyd, D.G., Zisterer, D.M. & Williams, D.C. , Flexible estrogen receptor modulators: design, synthesis and antagonistic effects in human MCF-7 breast cancer cells. , Journal Medicinal Chemistry, 44, (7), 2001, p1072 - 1084Journal Article, 2001, DOI , URL
• Zisterer, D.M., Campiani., Nacci, V. & Williams, D.C. , Pyrrolobenzoxazepines induce apoptosis in HL-60, Jurkat and Hut-78 cells: A new class of apoptotic agents., Journal Pharmacology and Experimental Therapeutics, 293, (1), 2000, p48 - 59Journal Article, 2000, URL
• Zisterer D.M., Campiani, G., Garafalo, A., Nacci, V. and Williams, D.C. , Antiproliferative action of pyrrolobenzoxazepine derivatives in cultured cells: Absence of correlation with binding to the peripheral-type benzodiazepine binding site, Biochemical Pharmacology, 55, (4), 1998, p397 - 403Journal Article, 1998, DOI , URL
• Zisterer, D.M. and Williams, D.C., Peripheral-type benzodiazepine receptors, General Pharmacology, 29, (3), 1997, p305 - 314Journal Article, 1997, DOI , URL
• Different specificities for taurine analogues and their target sites in brain. in, editor(s)Teelken and Korf , Neurochemistry, 1997, pp959 - 962, [19. Marangolo, M., Zisterer, D.M., Williams, D.C., Tipton, K.F., Dixon, H.B.F. and Della Corte, L.]Book Chapter, 1997
• Campiani G, Nacci V, Fiorini I, De Filippis MP, Garofalo A, Ciani SM, Greco G, Novellino E, Williams DC, Zisterer DM, Woods MJ, Mihai C, Manzoni C, Mennini T. , Synthesis, biological activity, and SARs of pyrrolobenzoxazepine derivatives, a new class of specific "peripheral-type" benzodiazepine receptor ligands., Journal of Medicinal Chemistry, 39, (18), 1996, p3435 - 3450Journal Article, 1996, DOI , URL
• Woods MJ, Zisterer DM, Williams DC. , Two cellular and subcellular locations for the peripheral-type benzodiazepine receptor in rat liver. , Biochemical Pharmacology, 51, (10), 1996, p1283 - 1292Journal Article, 1996, DOI , URL
• Zisterer DM, Gorman AM, Williams DC, Murphy MP. , The effects of the peripheral-type benzodiazepine acceptor ligands, Ro5-4864 and PK 11195, on mitochondrial respiration. , Methods and Findings in Experimental and Clinical Pharmacology, 14, (2), 1992, p85 - 90Journal Article, 1992, URL
• Meegan MJ, Hughes RB, Lloyd DG, Williams DC, Zisterer DM, Ethyl side-chain modifications in novel flexible antiestrogens--design, synthesis and biological efficacy in assay against the MCF-7 breast tumor cell line, Anticancer Drug Design , 16, (1), 2001, p57 - 69Journal Article, 2001, URL
• McGrath, LB, Onnis, V, Campiani, G, Williams, DC, Zisterer, DM and McGee, MM, Caspase-activated DNase (CAD)-independent oligonucleosomal DNA fragmentation in chronic myeloid leukaemia cells; a requirement for serine protease and Mn(2+)-dependent acidic endonuclease activity., Apoptosis, 11, (9), 2006, p1473 - 1487Journal Article, 2006, DOI , URL
• Lloyd, D.G., Smith, H.M., O'Sullivan, T., Knox, A.S., Zisterer, D.M. & Meegan, M.J. , Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes : Synthesis, Structure-Activity Relationships and Molecular Modeling Study for Flexible Estrogen Receptor Antagonists , Medicinal Chemistry, 2, (2), 2006, p147 - 168Journal Article, 2006, URL
• Smith, H.M., Knox, A.S., Zisterer, D.M., Lloyd, D.G., & Meegan, M.J. , Flexible estrogen receptor modulators: synthesis, biochemistry and molecular modeling studies for 3-benzyl-4,6-diarylhex-3-ene and 3,4,6-triarylhex-3-ene derivatives., Medicinal Chemistry, 3, (2), 2007, p135 - 155Journal Article, 2007
• Meegan, M.J., Barrett, I., Zimmmermann, J., Knox, A.J.S., Zisterer, D.M. & Lloyd, D.G. , Benzothiepin-derived molecular scaffolds for estrogen receptor modulators: synthesis and antagonistic effects in breast cancer cells. , Journal of Enzyme Inhibition and Medicinal Chemistry, 22, (5), 2007, p655-66Journal Article, 2007
• Greene, LM, Campiani, GC, Lawler, M, Williams, DC and Zisterer, DM, BubR1 is Required for a Sustained Mitotic Spindle checkpoint arrest in Human Cancer cells treated with a tubulin-targetting pyrrolo-1,5-benzoxazepine, Molecular Pharmacology, 73, (2), 2008, p419 - 430Journal Article, 2008, DOI , URL
• Nathwani, S-M., Butler, S., Meegan, M.J., Campiani, G., Lawler, M., Williams, D.C. & Zisterer, D.M., Dual targeting of tumour cells and host endothelial cells by novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines., Cancer Chemotherapy and Pharmacology, 65, (2), 2010, p289-300Journal Article, 2010, DOI , URL , TARA - Full Text
• Bane, F.T., Pennington, S.R., Campiani, G., Williams, D.C., Zisterer, D.M. & Mc Gee, M.M. , The microtubule-targeting agents, PBOX-6 [pyrrolobenzoxazepine 7-[(dimethylcarbamoyl)oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine] and paclitaxel, induce nucleocytoplasmic redistribution of the peptidyl-prolyl isomerases, cyclophilin A and pin1, in malignant hematopoietic cells., Journal of Pharmacology and Experimental Therapeutics, 329, 2009, p38-47Journal Article, 2009, DOI , URL
• Bright S.A., Greene, L.M., Greene, T.F., Campiani, G., Buitini, S., Brindisi, M., Lawler, M., Meegan, M.J., Williams, D.C. and Zisterer, D.M. , The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells, Biochemical Pharmacology, 77, (3), 2009, p310-321Journal Article, 2009, DOI , URL
• Barrett, I., Meegan, M.J., Hughes, R.B., Carr, M., Knox, A.J.S. Artemenko, N., Golfis, G., Zisterer, D.M. & Lloyd, D.G., Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators., Bioorganic & Medicinal Chemistry, 16, (21), 2008, p9554-9973Journal Article, 2008, DOI , URL
• Meegan, M.J., Carr, M., Knox, A.J.S., Zisterer, D.M. & Lloyd, D.G., Beta-Lactam type molecular scaffolds for antiproliferative activity: Synthesis and cytotoxic effects in breast cancer cells., Journal of Enzyme Inhibition and Medicinal Chemistry, 23, (5), 2008, p668-685Journal Article, 2008, DOI , URL
• Knox AJ, Meegan MJ, Sobolev V, Frost D, Zisterer DM, Williams DC, Lloyd DG., Target specific virtual screening: optimization of an estrogen receptor screening platform., Journal of Medicinal Chemistry, 50, (22), 2007, p5301-5310Journal Article, 2007, DOI , URL
• Verma NK, Dempsey E, Conroy J, Olwell P, Mcelligott AM, Davies AM, Kelleher D, Butini S, Campiani G, Williams DC, Zisterer DM, Lawler M, Volkov Y., A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin., Journal of Molecular Medicine, 86, (4), 2008, p457-469Journal Article, 2008, DOI
• Greene LM, Kelly L, Onnis V, Campiani G, Lawler M, Williams DC, Zisterer DM., STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells., Journal of Pharmacology and Experimental Therapeutics, 321, (1), 2007, p288-297Journal Article, 2007, DOI
• Mulligan JM, Greene LM, Cloonan S, Mc Gee MM, Onnis V, Campiani G, Fattorusso C, Lawler MP, Williams C, Zisterer DM., Identification of tubulin as the molecular target of pro-apoptotic pyrrolo-1,5-benzoxazepines., Molecular Pharmacology, 70, (1), 2006, p60-70Journal Article, 2006, DOI
• McElligott, AM, Maginn, EN, Greene, LM, McGuckin, S, Hayat, A, Browne, PV, Butini, S, Campiani, G, Catherwood, MA, Vandenberghe, E, Williams, DC, Zisterer, DM, Lawler, M, The Novel Tubulin-Targeting Agent Pyrrolo-1,5-Benzoxazepine-15 Induces Apoptosis in Poor Prognostic Subgroups of Chronic Lymphocytic Leukemia., Cancer Research, 69, (21), 2009, p8366 - 8375Journal Article, 2009, DOI
• Nathwani,SM, Butler, S, Fayne,D, McGovern,NN, Sarkardi,B, Meegan,MJ, Lloyd,DG, Campiani,G, Lawler,M, Williams,DC, and Zisterer, DM, Novel Microtubule targetting agents, pyrrolo-1,5,benzoxazepines induce apoptosis in multi-drug-resistant cancer cells, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 66, (3), 2010, p585 - 596Journal Article, 2010, DOI , URL , TARA - Full Text
• Barrett I, Carr M, O'Boyle N, Greene LM, Knox AJ, Lloyd DG, Zisterer DM, Meegan MJ, Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effects., Journal of enzyme inhibition and medicinal chemistry, 25, (2), 2010, p180-94Journal Article, 2010, DOI
• Sandra A. Bright, Giuseppe Campiani, Michael W. Deininger, Mark Lawler, D. Clive Williams and Daniela M. Zisterer, Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment , Biochemical Pharmacology, 80, 2010, p31 - 38Journal Article, 2010, DOI
• S A Bright, A M McElligott, J W O'Connell, L O'Connor, P Carroll, G Campiani, M W Deininger, E Conneally, M Lawler, D C Williams, and D.M Zisterer, Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo , British Journal of Cancer, 102, 2010, p1474 - 1482Journal Article, 2010, DOI , URL , TARA - Full Text
• Seema-Maria Nathwani , Suzanne M. Cloonan, Maeve Stronach, Giuseppe Campiani, Mark Lawler, D. Clive Williams and Daniela M. Zisterer, Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce cell cycle arrest and apoptosis in prostate cancer cells. , Oncology Reports, 24, 2010, p1499 - 1507Journal Article, 2010, DOI
• Greene LM, Nathwani SM, Bright SA, Fayne D, Croke A, Gargliardi M, Mc Elligott AM, O'Connor L, Carr M, Keely NO, O'Boyle NM, Carroll P, Sarkadi B, Conneally E, Lloyd DG, Lawler M, Meegan MJ, Zisterer DM, The vascular targeting agent Combretastatin-A4 and a novel cis-restricted {beta}-lactam analogue CA-432 induce apoptosis in human chronic myeloid leukemia cells and in ex vivo patient samples including those displaying multidrug resistance., The Journal of Pharmacology and Experimental Therapeutics, 335, (2), 2010, p302 - 313Journal Article, 2010, DOI
• Miriam Carr, Lisa M. Greene, Andrew J.S. Knox, David G Lloyd, Daniela M. Zisterer and Mary J. Meegan, Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects, European Journal of Medicinal Chemistry, 45, (12), 2010, p5752-5766Journal Article, 2010, DOI , URL , TARA - Full Text
• Maginn EN, Browne PV, Hayden P, Vandenberghe E, McDonagh B, Evans P, Goodyer M, Tewari P, Campiani G, Butini S, Williams DC, Zisterer DM, Lawler MP, McElligott AM., PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells., British Journal of Cancer, 104, (2), 2011, p281 - 289Journal Article, 2011, DOI
• O'Boyle, NM, Greene, LM, Bergin, O, Fichet, JB, McCabe, T, Lloyd, DG, Zisterer, DM, Meegan, MJ, Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones, Bioorganic & Medicinal Chemistry, 19, (7), 2011, p2306-2325Journal Article, 2011, DOI , URL , TARA - Full Text
• Forde JC, Maginn EN, McNamara G, Martin LM, Campiani G, Williams DC, Zisterer D, McElligott AM, Lawler M, Lynch TH, Hollywood D, Marignol L, Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitro., Cancer biology & therapy, 11, (4), 2011, p421-8Journal Article, 2011
• O'Boyle, NM, Carr, M, Greene, LM, Keely, NO, Knox, AJS, McCabe, T, Lloyd, DG, Zisterer, DM, Meegan, MJ, Synthesis, Biochemical and Molecular Modelling Studies of Antiproliferative Azetidinones causing Microtubule Disruption and Mitotic Catastrophe, European Journal of Medicinal Chemistry, 46, (9), 2011, p4595 - 4607Journal Article, 2011, DOI , URL , TARA - Full Text
• O'Boyle, N.M., Knox, A.J.S., Price, T.P., Williams, D.C., Zisterer, D.M., Lloyd, D.G., Meegan, M.J., Lead identification of beta-lactam and related imine inhibitors of the molecular chaperone heat shock protein 90, Bioorganic & Medicinal Chemistry, 19, (20), 2011, p6055-6068Journal Article, 2011, DOI , URL , TARA - Full Text
• O'Boyle NM, Carr M, Greene LM, Bergin O, Nathwani SM, McCabe T, Lloyd DG, Zisterer DM, Meegan MJ, Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents, Journal of Medicinal Chemistry, 53, (24), 2010, p8569-8584Journal Article, 2010, DOI , URL , TARA - Full Text
• Greene L.M., Carr M., Keeley N.O., Lawler M., Meegan M.J., Zisterer D.M., BubR1 is required for the mitotic block induced by combretastatin-A4 and a novel cis-restricted ß-lactam analogue in human cancer cells. , International Journal of Molecular Medicine, 27, (5), 2011, p715 - 723Journal Article, 2011
• Butini S., Gemma S., Brindisi M., Borrelli G., Lossani A., Ponte A.M., Torti A., Maga G., Marinelli L., La Pietra V., Fiorini I., Lamponi S., Campiani G., Zisterer D.M., Nathwani S.M., Sartini S., La Motta C., Da Settimo F., Novellino E., Focher F. , Non-nucleoside inhibitors of human adenosine kinase: synthesis, molecular modeling, and biological studies. , Journal of Medicinal Chemistry, 54, (5), 2011, p1401 - 1420Journal Article, 2011
• Greene LM, Wang S, O'Boyle NM, Bright SA, Reid JE, Kelly P, Meegan MJ, Zisterer DM, Combretazet-3 a novel synthetic cis-stable combretastatin A-4-azetidinone hybrid with enhanced stability and therapeutic efficacy in colon cancer., Oncology reports, 29, (6), 2013, p2451-8Journal Article, 2013
• Greene, LM, O'Boyle, NM, Nolan, DP, Meegan, MJ, Zisterer, DM, The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells, BIOCHEMICAL PHARMACOLOGY, 84, (5), 2012, p612-624Journal Article, 2012, DOI
• O'Boyle, NM, Greene, LM, Keely, NO, Wang, S, Cotter, TS, Zisterer, DM, Meegan, MJ, Synthesis and biochemical activities of antiproliferative amino acid and phosphate derivatives of microtubule-disrupting beta-lactam combretastatins, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 62, 2013, p705-721Journal Article, 2013, DOI
• Nathwani, SM, Hughes, L, Greene, LM, Carr, M, O'Boyle, NM, McDonnell, S, Meegan, MJ, Zisterer, DM, Novel cis-restricted beta-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro, ONCOLOGY REPORTS, 29, (2), 2013, p585-594Journal Article, 2013, DOI
• Kahvedzic, A, Nathwani, SM, Zisterer, DM, Rozas, I, Aromatic Bis-N-hydroxyguanidinium Derivatives: Synthesis, Biophysical, and Biochemical Evaluations, Journal of Medicinal Chemistry, 56, (2), 2013, p451-459Journal Article, 2013, DOI
• Lysaght, J, Verma, NK, Maginn, EN, Ryan, JM, Campiani, G, Zisterer, DM, Williams, DC, Browne, PV, Lawler, MP, McElligott, AM, The microtubule targeting agent PBOX-15 inhibits integrin-mediated cell adhesion and induces apoptosis in acute lymphoblastic leukaemia cells, INTERNATIONAL JOURNAL OF ONCOLOGY, 42, (1), 2013, p239-246Journal Article, 2013, DOI
• Keely, NO, Zisterer, DM, Meegan, MJ, Design, Synthesis and Biochemical Evaluation of Estrogen Receptor Ligand Conjugates as Tumour Targeting Agents, LETTERS IN DRUG DESIGN & DISCOVERY, 9, (3), 2012, p295-304Journal Article, 2012
• Greene LM, Nolan DP, Regan-Komito D, Campiani G, Williams DC, Zisterer DM, Inhibition of late-stage autophagy synergistically enhances pyrrolo-1,5-benzoxazepine-6-induced apoptotic cell death in human colon cancer cells., International journal of oncology, 2013Journal Article, 2013
• Bane, F.T., Bannon, J.H., Pennington, S.R., Campiani, G., Williams, D.C., Zisterer, D.M., Mc Gee, M.M., The microtubule-targeting agents, PBOX-6 [Pyrrolobenzoxazepine 7-[(dimethylcarbamoyl)oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine] and paclitaxel, induce nucleocytoplasmic redistribution of the peptidyl-prolyl isomerases, cyclophilin A and Pin1, in malignant hematopoietic cells (Journal of Pharmacology and Experimental Therapeut (2009) 329, (38-47)), 2011, p729Journal Article, 2011
• Gangemi G, Gazzerro P, Fiore D, Proto MC, Butini S, Gemma S, Casagni A, Laezza C, Vitale M, Ligresti A, Di Marzo V, Zisterer DM, Nathwani S, Clive Williams D, Campiani G, Bifulco M, PBOX-15 induces apoptosis and improves the efficacy of oxaliplatin in human colorectal cancer cell lines., European journal of pharmacology, 2013Journal Article, 2013
• Lennon JC, Bright SA, Carroll E, Butini S, Campiani G, O'Meara A, Williams DC, Zisterer DM, The novel pyrrolo-1,5-benzoxazepine, PBOX-6, synergistically enhances the apoptotic effects of carboplatin in drug sensitive and multidrug resistant neuroblastoma cells., Biochemical pharmacology, 87, (4), 2014, p611-24Journal Article, 2014
• O'Boyle, NM, Pollock, JK, Carr, M, Knox, AJS, Nathwani, SM, Wang, S, Caboni, L, Zisterer, DM, Meegan, MJ, Beta-Lactam Estrogen Receptor Antagonists and a Dual-Targeting Estrogen Receptor/Tubulin Ligand, Journal of Medicinal Chemistry, 57, (22), 2014, p9370 - 9382Journal Article, 2014, DOI , URL , TARA - Full Text
• Pollock, JK, Verma,NK, O'Boyle, NM, Carr, MG, Meegan, MJ, Zisterer, DM, Combretastatin (CA)-4 and its novel analogue CA-432 impair T-cell migration through the Rho/ROCK signalling pathway, Biochemical Pharmacology, 92, (4), 2014, p544-557Journal Article, 2014, DOI
• Greene, LM, Wang, S, O'Boyle, NM, Bright, SA, Reid, JEA, Kelly, PJ, Meegan, MJ, Zisterer, DM, Combretazet-3 a novel synthetic cis-stable combretastatin A-4-azetidinone hybrid with enhanced stability and therapeutic efficacy in colon cancer, Oncology Reports, 29, (6), 2013, p2451-2458Journal Article, 2013, DOI
• Greene, LM, O'Boyle, NM, Nolan, DP, Meegan, MJ, Zisterer, DM, The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells, Biochemical Pharmacology, 84, (5), 2012, p612-624Journal Article, 2012, DOI
• Barrett, I., Carr, M.G., O'Boyle, N.M., Greene, L.M., Knox, A., Lloyd, D.G., Zisterer, D.M., Meegan, M.J., Lead identification of conformationally restricted benzoxepin type combretastatin analogs: Synthesis, antiproliferative activity, and tubulin effects, Journal of Enzyme Inhibition and Medicinal Chemistry, 25, (2), 2010, p180-194Journal Article, 2010, DOI
• Greene,. L.M., Nathwani, S.M., Bright, S.A., Fayne, D., Croke, A., Gagliardi,M., McElligott, A.M., O'Connor, L.M., Carr, M.G., Keely, N.O., O'Boyle, N.M., Carroll, P.V., Sarkadi, B., Conneally, E.C., Lloyd,D.G., Lawler, M.P., Meegan, M.J., Zisterer, D.M., The vascular targeting agent combretastatin-A4 and a novel cis-restricted beta-lactam analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance, Journal of Pharmacology and Experimental Therapeutics, 335, (2), 2010, p302-313Journal Article, 2010, DOI

• Magnano, S., O'Sullivan, J. and Zisterer, D.M., Pre-clinical evaluation of targeting autophagy for the treatment of Oral Squamous Cell Carcinoma , IADR Irish Divison, Belfast, November 2nd 2017, 2017Poster
• Niamh M. O'Boyle, Daniela M. Zisterer, Mary J. Meegan, Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERalpha and ERbeta Activity, Proceedings of the 3rd Int. Electron. Conf. Med. Chem., 3rd International Electronic Conference on Medicinal Chemistry, November 2017, edited by Annie Mayence and Jean Jacques Vanden Eynde , 11, (1), Pharmaceuticals, 2017, pp18-Conference Paper, DOI , URL
• Niamh M. O'Boyle, Daniela M. Zisterer, Mary J. Meegan, Microtubule-Destabilising Actions of Piperlongumine and Analogues, Proceedings of the 3rd Int. Electron. Conf. Med. Chem., 3rd International Electronic Conference on Medicinal Chemistry, November 2017, edited by Annie Mayence and Jean Jacques Vanden Eynde , 11, (1), Pharmaceuticals, 2017, pp18-Conference Paper, DOI , URL
• Amet R, Rozas I, McElligott AM, Browne P and Zisterer DM, Novel Anti-Cancer Therapeutics for Multiple Myeloma that target the STAT3 signalling pathway, Irish Association Cancer Research, Crowne Plaza Hotel, Santry, Dublin, 22nd February 2018, 2018Poster
• Amet R., Previtali V., Browne P.V., Rozas I., McElligott A.M. & Zisterer D.M. , Novel anti-cancer therapeutics for multiple myeloma which target the STAT3 signalling pathway , European Association for Cancer Research, Amsterdam Netherlands, 1 to 3 february 2018, 2018Poster
• Coyle R, O'Sullivan M. & Zisterer DM, Inhibitor of Apoptosis Proteins as Targets for the Treatment of Malignant Rhabdoid Tumor, European Association for Cancer Research, Amsterdam Netherlands, 1 to 3 february 2018, 2018Poster
• Coyle R, O'Sullivan M. & Zisterer DM, Inhibitor of Apoptosis Proteins as Targets for the Treatment of Malignant Rhabdoid Tumor, Irish Association Cancer Research, Crowne Plaza Hotel, Santry, Dublin, 22nd February 2018, 2018Poster
• Amet R, Rozas I, McElligott AM, Browne P and Zisterer DM , Novel Anti-Cancer Therapeutics for Multiple Myeloma that target the STAT3 signalling pathway,, Haematology Association of Ireland, Galway, 11th October , 2019Invited Talk
• Magnano, S., O'Sullivan, J. and Zisterer, D.M., Role of Autophagy in Chemoresistance in Oral Squamous Cell Carcinoma, International Association for Dental Research, London, England, 25 July , 2018Invited Talk
• Eavan C. McLoughlin, Patricia Hannon Barroeta, Daniela M. Zisterer, and Niamh M. O'Boyle, P41: A comparison of chiral diastereomeric versus kinetic enzymatic resolution for enantioseparation of microtubule depolymerising beta-lactams, 30th Annual GP2A Medicinal Chemistry Conference, Dublin, 24-26 August 2022, 2022Poster

There is a continuing requirement for increased understanding of the molecular events underlying the development of cancer. Deregulated apoptosis is a primary cause of tumour development, therefore an increased understanding of this processes will lead to development of novel therapies which target components of this deregulated pathway. In addition, cancer cells are highly adept at surviving under conditions of physiological stress. The autophagy pathway has been identified as a critical cell survival pathway that underpins cellular metabolism. In tumours, deregulation of autophagy frequently occurs contributing to both establishment of neoplastic disease through genomic instability and survival of cancer cells. Autophagy has thus acquired an emerging interest in cancer research offering novel therapeutic targets. Our research programme seeks to understand the molecular mechanisms underlying apoptotic cell death and how deregulated apoptosis leads to cancer. We aim to develop novel therapies which target components of this deregulated pathway. Furthermore, we are interested in determining how tumour resistance to chemotherapy relates to cell survival through autophagic mechanisms. Dr Zisterer has published over one hundred research articles in highly ranked international journals including British Journal of Cancer, Journal of Biological Chemistry and Cancer Research. To date, she has supervised or co-supervised 18 PhD students to completion. She has secured over €3.9 million in research funding from a variety of sources including the European Union, Science Foundation Ireland and the Health Research Board. She is currently project coordinator of an international, inter-sectoral Horizons 2020 Marie Skłodowska-Curie innovative PhD training network entitled Training in Cancer mechanisms and Therapeutics (TRACT), which has secured funding of €2.9 million.

• Title

  Molecular and Cellular Mechanisms underlying inflammatory processes
  Summary
  Funding Agency

  PRTLI
  Date From

  1/9/2012
  Date To

  31/8/2015
• Title

  Platinum complexes of guanidinium based DNA minor groove binders: conjugating forces towards better anticancer agents
  Summary
  Funding Agency

  Science Foundation ireland
  Date From

  2011
  Date To

  2015
• Title

  Cancer, tubulin and free radicals: new therapy
  Summary
  Funding Agency

  Irish Research Council
  Date From

  1/3/2013
  Date To

  28/2/2015
• Title

  Inhibitors of apoptosis proteins as targets for treatment of malignant rhabdoid tumours
  Summary
  Funding Agency

  Trinity College Dublin
  Date From

  1/9/2015
  Date To

  30/8/2018
• Title

  Evaluation of the anti-cancer effects of novel pyrrolobenzoxazepines (PBOXs) in gastrointestinal stromal tumours
  Summary
  Funding Agency

  Health Research Board
  Date From

  January 2012
  Date To

  January 2015
• Title

  Training in Cancer Mechanisms & Therapeutics (TRACT)
  Summary
  Funding Agency

  EU Horizon 2020
  Date From

  1/10/2016
  Date To

  30/9/2020
• Title

  Evaluation of the effect of novel pyrrolobenzoxazepines on primary leukaemia stem cells and on NOTCH signalling in paediatric acute leukaemia cells
  Summary
  Funding Agency

  Children's Leukaemia Research Project
  Date From

  1/3/2015
  Date To

  28/2/2016
• Title

  Chemotype switching for identification and mechanistic deconvolution of novel apoptotic agents
  Summary
  Funding Agency

  Health Research Board
  Date From

  2004
  Date To

  2007
• Title

  Evaluation of pyrrolobenzoxazepines as novel anti-angiogenic agents
  Summary
  Funding Agency

  Enterprise Ireland
  Date From

  2005
  Date To

  2006
• Title

  Novel Therapeutic Strategies for Malignant Rhabdoid Tumours
  Summary
  Funding Agency

  TCD
  Date From

  1/9/2018
  Date To

  30/8/2022
• Title

  2006Spectroscopic and calorimetric analysis of native and mutant proteins.
  Summary
  Funding Agency

  Science Foundation Ireland
  Date From

  2006
• Title

  The use of pyrrolo-1,5-benzoxazepine as powerful probes to dissect components of apoptotic cell death signalling and their development as anti-cancer therapeutics
  Summary
  Funding Agency

  Science Foundation Ireland
  Date From

  2005
  Date To

  2009
• Title

  Evaluation of TRAIL sensitisation of childhood acute leukaemia cells by novel pyrrolobenzoxazepines
  Summary
  Funding Agency

  Children's Leukaemia Research Project
  Date From

  October 2011
  Date To

  October 2015
• Title

  Stat3 signalling as a therapeutic target in Multiple Myeloma
  Summary
  Funding Agency

  School of Medicine, Trinity College Dublin
  Date From

  1/9/2016
  Date To

  30/8/2019
• Title

  Development of pyrrolo-1,5-benzoxazepine as novel anti-cancer therapeutics
  Summary
  Funding Agency

  Enterprise Ireland
  Date From

  2003
  Date To

  2005
• Title

  Evaluation of the anti-cancer effects of novel pyrrolobenzoxazepines in neuroblastoma
  Summary
  Funding Agency

  National Children's Hospital Crumlin
  Date From

  October 2010
  Date To

  October 2014
• Title

  Rational design of dual targeting anti-cancer agents: novel ligands for hsp90 and tubulin.
  Summary
  Funding Agency

  Science Foundation Ireland
  Date From

  2006
  Date To

  2009
• Title

  Development of new diagnostic, prognostic and therapeutic agents in prostate cancer
  Summary
  Funding Agency

  Irish Cancer Society
  Date From

  2003
  Date To

  2006
• Title

  Synthesis and biological evaluation of novel combretastatin analogues
  Summary
  Funding Agency

  Health Research Board
  Date From

  2009
  Date To

  2012

Biochemistry and cell biology, Cancer, Pharmacology and pharmaceutical sciences,

• John Scott Fellowship 2016
• Fellowship of Trinity College Dublin 2007
• Provost's PhD Award 2018

• Treasurer of the Irish Area Section of the Biochemical Society Present
• Membership of the Irish Association of Cancer Research present

• Member, Core Technology PI's, DMMC Principal Investigators leading the development of core technology platforms.
• Coordinator of cancer strand of PRTLI-funded PhD programme 'Molecular and Cellular Mechanisms underlying inflammatory processes in Neuroscience, Infection & Immunity and Cancer' 2011
• Member, Centre for Molecular Research in Cancer (Proposed), This consortium combines researchers with common interest in understanding cell cycle signaling and regulation with specific focus on two key cancer-related processes (cell cycle control, apoptosis) and/or three specific malignancy types (oesophageal, prostate and haematological).
• Member, DMMC Cancer Principal Investigators, Trans-institutional grouping of Principal Investigators leading research on Cancer themes
• Coordinator of H2020-MSCA-Innovative Training Network entitled TRACT (Training in Cancer Mechanisms & Therapeutics) with budget of 2.9 million. 2016
• Member, Prostate Cancer Research Consortium, Multi-centred consortium focused on the development of new diagnostic, prognostic and therapeutic agents for application in prostate cancer.
• Member of the Trinity Biomedical Sciences Institute Cancer Drug Discovery Centre September 2011